Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company’s antibody drug conjugate (ADC) platform using Akari’s spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells. This patent application represents a new patent family to further extend Akari’s proprietary position with respect to the Company’s novel payload, PH1 (a novel Thailanstatin analog).

Read more at globenewswire.com